Cholangiocarcinoma research studies

Author: lyxf

August undefined, 2024

WebMar 29, 2024 · Citation, DOI, disclosures and article data. Cholangiocarcinomas (commonest type of bile duct cancers) are malignant epithelial tumors arising from the biliary tree, excluding the gallbladder or ampulla of Vater. Cholangiocarcinoma is the third most common primary hepatobiliary malignancy after hepatocellular carcinoma (HCC) and … WebJan 1, 2024 · Among these, the BILCAP study reported longer median OS in patients treated with standard capecitabine compared with those receiving placebo (53 months versus 36 months respectively, Hazard Ratio [HR] 0.75, 95% CI 0.58–0.97; p = 0.028) in the pre-specified intention-to-treat sensitivity analysis adjusted for prognostic factors such as …

Clinicopathological characteristics and prognostic factors for

WebBackground & aims: Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer, whose incidence and related mortality is increasing. This study investigates the clinical course of CCA and subtypes (intrahepatic [iCCA], perihilar [pCCA], and distal [dCCA]) in a pan-European cohort. WebDescription. Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. … 24瓦时

Multidisciplinary management in the treatment of intrahepatic ...

WebA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors. This phase II trial studies how well olaparib works in treating … WebIn order to obtain comprehensive data, research studies require diverse participants. This is especially important for certain populations, such as adults aged 75 years or older, people from different ethnic and racial groups, people from different socioeconomic backgrounds, and other underrepresented communities such as LGBTQ and persons with ... WebFGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with pre … 24瓶农夫山泉

Associations between ultrasound screening findings and ... - Nature

Cholangiocarcinoma Workup: Laboratory Studies, …

WebFeb 3, 2024 · Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. WebOct 11, 2024 · Adjuvant Transcatheter Arterial Chemoembolization for Intrahepatic Cholangiocarcinoma after Curative Surgery: Retrospective Control Study. World J Surg. 2011 Jun 23. [QxMD MEDLINE Link]. … 24瓦灯适合多少平米WebAug 6, 2024 · Data sources. Data from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand were used for this study. CASCAP is the first project for large scale CCA screening in Thailand. 24瓦灯多亮

"WebAs a result of an explosion of research in the field, the first such targeted therapy, pemigatinib (Pemazyre), was approved in April 2024 for patients with unresectable, … " - Cholangiocarcinoma research studies

Cholangiocarcinoma research studies

Immune-related adverse events correlate with the efficacy of PD-1 ...

WebJun 1, 2024 · A variety of factors have been used to predict prognosis after surgical resection for ECC, but no consensus has been reached. Therefore, this study sought to identify useful prognostic factors for patients with ECC. In our institution, within the study period, 76 patients received surgical resection for mid to distal cholangiocarcinoma. WebWhen found to be safe and helpful, they may become tomorrow’s standard of care. Clinical trials can study many things, such as: New drugs not yet approved by the U.S. FDA ( F …

Did you know?

WebThe most common oncogenic comutations identified in this study were PI3KCA, KRAS, BRAF, and FGFR2, consistent with a previous report on ivosidenib. 18 No significant association was found between comutations in any single gene and OS, PFS, or treatment duration in this large data set—an important factor for this type of analysis—of patients ... WebBackground: Median survival of patients with non-resectable hilar cholangiocarcinoma is 3 to 6 months, even after biliary drainage. Therefore, a single-arm phase II study was conducted (July 1996 to October 1998) to investigate the effect of local photodynamic therapy; a significant improvement in survival (74%) was noted at 6 months.

WebApr 14, 2024 · Cholangiocarcinoma [], a biliary tract cancer, is the second most common cause of hepatic cancer-related deaths.CCA is characterized by an increasing annual incidence and an unsatisfactory treatment outcome. Indeed, a considerable fraction of patients under systemic chemotherapy for advanced unresectable CCA fails to respond … WebTable 1 shows the major features of the research studies in the meta-analysis. 21–27 The research studies were carried out in the following nations: one in China, Taiwan, and Korea, respectively, and four in the USA. The design of case–control was included in all the research studies. A total of 413,483 healthy controls and 8,962 subjects were chosen to …

WebIn a whole-exome-sequencing study of 231 cholangiocarcinoma tumour samples 92, a median of 39 and 35 somatic nonsynonymous mutations were identified in intrahepatic … WebAmong other studies, TargetCancer Foundation has supported research into the functions of the IDH1 and 2 genes, which are mutated in about 30% of intrahepatic …

WebApr 10, 2024 · Background: Laparoscopic liver resection (LLR) is controversial in treating intrahepatic cholangiocarcinoma (ICC). Therefore, this study aimed to evaluate the safety and feasibility of LLR for the treatment of ICC and explored the independent factors affecting the long-term prognosis of ICC.

WebJun 30, 2024 · José J. G. Marin, Maria Giuseppina Prete, … on behalf of the working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma ... 24瓦特WebTable 1 shows the major features of the research studies in the meta-analysis. 21–27 The research studies were carried out in the following nations: one in China, Taiwan, and … 24瓶啤酒WebA Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors. This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or … 24瓶矿泉水尺寸WebApr 10, 2024 · Background: Laparoscopic liver resection (LLR) is controversial in treating intrahepatic cholangiocarcinoma (ICC). Therefore, this study aimed to evaluate the … 24生地舰炮WebAug 25, 2024 · This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDy), and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic cholangiocarcinoma (CCA) and other solid tumors. 24瓶可乐WebMar 19, 2024 · This study is registered with EudraCT, number 2005-003318-13. Findings: Between March 15, 2006, and Dec 4, 2014, 447 patients were enrolled; 223 patients with biliary tract cancer resected with curative intent were randomly assigned to the capecitabine group and 224 to the observation group. 24瓶矿泉水是多少升WebFeb 10, 2024 · The study, called TOPAZ-1, found that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy modestly extended how long people with advanced biliary tract cancer lived. TOPAZ-1 is the first large clinical trial to show that initial, or first-line, treatment that includes immunotherapy can improve survival in patients with ... 24生命ja共済